---
title: "Imunon announces press release available"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293625903.md"
description: "Imunon announced new data for IMNN-001 to be presented at AACR D3. The Phase 2 OVATION-2 results showed a median overall survival of 40.5 months versus 27.6 months with chemotherapy alone. Additionally, the company highlighted the rapidly recruiting Phase 3 OVATION-3 trial, which is pivotal for a potential BLA filing."
datetime: "2026-07-23T13:25:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293625903.md)
  - [en](https://longbridge.com/en/news/293625903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293625903.md)
---

# Imunon announces press release available

-   Imunon released a July 23, 2026 announcement on new IMNN-001 data set for presentation at AACR D3 in Boston, July 21-24. \* Poster highlights Phase 2 OVATION-2 results: median overall survival 40.5 months vs. 27.6 months with chemotherapy alone; final results cited 45.1 vs. 30.4. \* Update also points to a rapidly recruiting Phase 3 OVATION-3 trial, positioned as pivotal for a potential BLA filing if successful. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230925PRIMZONEFULLFEED9766830) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IMNN.US](https://longbridge.com/en/quote/IMNN.US.md)

## Related News & Research

- [Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan](https://longbridge.com/en/news/294371031.md)
- [EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study](https://longbridge.com/en/news/294368697.md)
- [Alvotech announces successful closure of FDA inspection of manufacturing facility | ALVO Stock News](https://longbridge.com/en/news/294216022.md)
- [New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS | INCY Stock News](https://longbridge.com/en/news/294608245.md)
- [Alvotech says FDA closes Reykjavik plant inspection with VAI classification](https://longbridge.com/en/news/294215716.md)